BA
LGND icon

Bellwether Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Bellwether Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$4K – 580
2021
Q2 		$4K Buy
+50
New +$4.16K ﹤0.01% 338

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Bellwether Advisors's LGND Position: Q3 2021 in Review

Bellwether Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2021, closing a stake of 50 shares — an estimated $4K sold.

Bellwether Advisors first reported a position in LGND in Q2 2021 and held it in 1 quarter. The position peaked at $4K in Q2 2021. 207 funds tracked by Wall St. Rank hold LGND as of Q3 2021.

  • Bellwether Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bellwether Advisors sold 50 Ligand Pharmaceuticals shares in Q3 2021, an estimated $4K.
  • Bellwether Advisors first reported a position in Ligand Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Bellwether Advisors's Ligand Pharmaceuticals position peaked at $4K in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2021.

Based on Bellwether Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.